Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL-EVOLVE: Ponatinib vs Imatinib and Blinatumomab in Ph+ ALL
NCT06061094Phase 2Recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Jul 2023
- Primary completion
- Jul 2029
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ponatinib and blinatumomab in Acute lymphoblastic leukemia, Philadelphia chromosome positive (5 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Overall Survival up to 4 years. Started Jul 2023; status: recruiting.
02
Drugs
ponatinibblinatumomab
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT06061094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06061094.